Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma

Joseph Kim, Armando E. Giuliano, Roderick R. Turner, Robyn E. Gaffney, Naoyuki Umetani, Minoru Kitago, David Elashoff, Dave S B Hoon

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

OBJECTIVE: To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma. SUMMARY BACKGROUND DATA: BRAF gene mutation is frequently detected in papillary thyroid carcinoma. Its role in pathogenesis or progression is under investigation. METHODS: Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued. BRAF mutation was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR assay. RESULTS: Tissue specimens from 103 consecutive patients were evaluated. BRAF mutation of the primary tumor was detected in 34 (33%) patients. In 26 of 34 (76%) patients with BRAF mutation, concomitant lymph node metastasis was detected. On the contrary, in 69 patients with BRAF mutation-negative primary tumors, only 12 (17%) patients had lymph node metastasis (χ, P < 0.0001). BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative primary tumors. Univariate analysis identified age, stage, tumor size, and BRAF mutation as prognostic factors for lymph node metastasis. In multivariate analysis, only BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence interval, 3.5-34.0, P < 0.0001). CONCLUSIONS: BRAF mutation may be a key genetic factor for the metastatic progression of papillary thyroid carcinoma. The study demonstrates that this gene mutation is a significant risk factor for locoregional lymph node metastasis and has potential utility as a surrogate marker.

Original languageEnglish
Pages (from-to)799-804
Number of pages6
JournalAnnals of Surgery
Volume244
Issue number5
DOIs
Publication statusPublished - 2006 Nov
Externally publishedYes

Fingerprint

Mutation
Genes
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Papillary Thyroid cancer
Sentinel Lymph Node Biopsy
Thyroidectomy
Real-Time Polymerase Chain Reaction
Multivariate Analysis
Biomarkers
Odds Ratio
Confidence Intervals

ASJC Scopus subject areas

  • Surgery

Cite this

Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R. E., Umetani, N., Kitago, M., ... Hoon, D. S. B. (2006). Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Annals of Surgery, 244(5), 799-804. https://doi.org/10.1097/01.sla.0000224751.80858.13

Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. / Kim, Joseph; Giuliano, Armando E.; Turner, Roderick R.; Gaffney, Robyn E.; Umetani, Naoyuki; Kitago, Minoru; Elashoff, David; Hoon, Dave S B.

In: Annals of Surgery, Vol. 244, No. 5, 11.2006, p. 799-804.

Research output: Contribution to journalArticle

Kim, J, Giuliano, AE, Turner, RR, Gaffney, RE, Umetani, N, Kitago, M, Elashoff, D & Hoon, DSB 2006, 'Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma', Annals of Surgery, vol. 244, no. 5, pp. 799-804. https://doi.org/10.1097/01.sla.0000224751.80858.13
Kim, Joseph ; Giuliano, Armando E. ; Turner, Roderick R. ; Gaffney, Robyn E. ; Umetani, Naoyuki ; Kitago, Minoru ; Elashoff, David ; Hoon, Dave S B. / Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. In: Annals of Surgery. 2006 ; Vol. 244, No. 5. pp. 799-804.
@article{a18b7c34b7be4feeba74cd6ddcffde86,
title = "Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma",
abstract = "OBJECTIVE: To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma. SUMMARY BACKGROUND DATA: BRAF gene mutation is frequently detected in papillary thyroid carcinoma. Its role in pathogenesis or progression is under investigation. METHODS: Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued. BRAF mutation was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR assay. RESULTS: Tissue specimens from 103 consecutive patients were evaluated. BRAF mutation of the primary tumor was detected in 34 (33{\%}) patients. In 26 of 34 (76{\%}) patients with BRAF mutation, concomitant lymph node metastasis was detected. On the contrary, in 69 patients with BRAF mutation-negative primary tumors, only 12 (17{\%}) patients had lymph node metastasis (χ, P < 0.0001). BRAF mutation was detected in 20 of 26 (77{\%}) lymph node metastases matched to BRAF mutation-positive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative primary tumors. Univariate analysis identified age, stage, tumor size, and BRAF mutation as prognostic factors for lymph node metastasis. In multivariate analysis, only BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95{\%} confidence interval, 3.5-34.0, P < 0.0001). CONCLUSIONS: BRAF mutation may be a key genetic factor for the metastatic progression of papillary thyroid carcinoma. The study demonstrates that this gene mutation is a significant risk factor for locoregional lymph node metastasis and has potential utility as a surrogate marker.",
author = "Joseph Kim and Giuliano, {Armando E.} and Turner, {Roderick R.} and Gaffney, {Robyn E.} and Naoyuki Umetani and Minoru Kitago and David Elashoff and Hoon, {Dave S B}",
year = "2006",
month = "11",
doi = "10.1097/01.sla.0000224751.80858.13",
language = "English",
volume = "244",
pages = "799--804",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma

AU - Kim, Joseph

AU - Giuliano, Armando E.

AU - Turner, Roderick R.

AU - Gaffney, Robyn E.

AU - Umetani, Naoyuki

AU - Kitago, Minoru

AU - Elashoff, David

AU - Hoon, Dave S B

PY - 2006/11

Y1 - 2006/11

N2 - OBJECTIVE: To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma. SUMMARY BACKGROUND DATA: BRAF gene mutation is frequently detected in papillary thyroid carcinoma. Its role in pathogenesis or progression is under investigation. METHODS: Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued. BRAF mutation was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR assay. RESULTS: Tissue specimens from 103 consecutive patients were evaluated. BRAF mutation of the primary tumor was detected in 34 (33%) patients. In 26 of 34 (76%) patients with BRAF mutation, concomitant lymph node metastasis was detected. On the contrary, in 69 patients with BRAF mutation-negative primary tumors, only 12 (17%) patients had lymph node metastasis (χ, P < 0.0001). BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative primary tumors. Univariate analysis identified age, stage, tumor size, and BRAF mutation as prognostic factors for lymph node metastasis. In multivariate analysis, only BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence interval, 3.5-34.0, P < 0.0001). CONCLUSIONS: BRAF mutation may be a key genetic factor for the metastatic progression of papillary thyroid carcinoma. The study demonstrates that this gene mutation is a significant risk factor for locoregional lymph node metastasis and has potential utility as a surrogate marker.

AB - OBJECTIVE: To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma. SUMMARY BACKGROUND DATA: BRAF gene mutation is frequently detected in papillary thyroid carcinoma. Its role in pathogenesis or progression is under investigation. METHODS: Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued. BRAF mutation was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR assay. RESULTS: Tissue specimens from 103 consecutive patients were evaluated. BRAF mutation of the primary tumor was detected in 34 (33%) patients. In 26 of 34 (76%) patients with BRAF mutation, concomitant lymph node metastasis was detected. On the contrary, in 69 patients with BRAF mutation-negative primary tumors, only 12 (17%) patients had lymph node metastasis (χ, P < 0.0001). BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative primary tumors. Univariate analysis identified age, stage, tumor size, and BRAF mutation as prognostic factors for lymph node metastasis. In multivariate analysis, only BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence interval, 3.5-34.0, P < 0.0001). CONCLUSIONS: BRAF mutation may be a key genetic factor for the metastatic progression of papillary thyroid carcinoma. The study demonstrates that this gene mutation is a significant risk factor for locoregional lymph node metastasis and has potential utility as a surrogate marker.

UR - http://www.scopus.com/inward/record.url?scp=33750308218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750308218&partnerID=8YFLogxK

U2 - 10.1097/01.sla.0000224751.80858.13

DO - 10.1097/01.sla.0000224751.80858.13

M3 - Article

C2 - 17060774

AN - SCOPUS:33750308218

VL - 244

SP - 799

EP - 804

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 5

ER -